Surrogacy of tumor response and progression-free survival for overall survival in metastatic breast cancer resistant to both anthracyclines and taxanes

International Journal of Clinical Oncology

Volumn 16, Issue 6, 2011, Pages 623-629

  Matsubara, Yoshihiro ^a   Sakabayashi, Satomi ^a   Nishimura, Tsutomu ^a   Ishida, Takanori ^b   Ohuchi, Noriaki ^b   Teramukai, Satoshi ^c   Fukushima, Masanori ^a  

^a Translational Research Informatics Center   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Surrogacy; Surrogate endpoint; Survival; Tumor response

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CREATININE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; METASTASIS; NEUTROPHIL COUNT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CREATININE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; SURVIVAL RATE; TAXOIDS;

EID: 84855203259     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0231-5     Document Type: Article

References (22)

1. U.S. Department of Health and Human Services Food and Drug Administration (2007) Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics
2. NT Ueno AU Buzdar SE Singletary, et al. 1997 Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center Cancer Chemother Pharmacol 40 321 329 9225950 10.1007/ s002800050664 1:STN:280:DyaK2szmvFClsA%3D%3D (Pubitemid 27276136)
3. CD Berg SM Swain 1994 Results of concomitantly administered chemoradiation for locally advanced noninflammatory breast cancer Semin Radiat Oncol 4 226 235 10717111 10.1016/S1053-4296(05)80093-1 (Pubitemid 24312243)
4. T Ishida T Kiba M Takeda, et al. 2009 Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes Cancer Chemother Pharmacol 64 361 369 19082596 10.1007/s00280-008-0882-8 1:CAS:528:DC%2BD1MXms1agu78%3D
5. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
6. P Bruzzi L Del Mastro MP Sormani, et al. 2005 Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients J Clin Oncol 23 5117 5125 15955906 10.1200/JCO.2005.02.106 (Pubitemid 46224020)
7. T Burzykowski M Buyse MJ Piccart-Gebhart, et al. 2008 Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer J Clin Oncol 26 1987 1992 18421050 10.1200/JCO.2007.10.8407 1:CAS:528:DC%2BD1cXlvFaqs70%3D
8. A Hackshaw A Knight P Barrett-Lee, et al. 2005 Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer Br J Cancer 93 1215 1221 16278665 10.1038/sj.bjc.6602858 1:CAS:528:DC%2BD2MXht1ems7vP (Pubitemid 41679406)
9. CJ Weir RJ Walley 2006 Statistical evaluation of biomarkers as surrogate endpoints: a literature review Stat Med 25 183 203 16252272 10.1002/sim.2319 (Pubitemid 43141502)
10. Baker SG (2006) Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst 98:502-503 (Pubitemid 43898811)
11. RL Prentice 1989 Surrogate endpoints in clinical trials: definition and operational criteria Stat Med 8 431 440 2727467 10.1002/sim.4780080407 1:STN:280:DyaL1M3ms1aktg%3D%3D (Pubitemid 19105891)
12. PA Greenberg GN Hortobagyi TL Smith, et al. 1996 Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 2197 2205 8708708 1:CAS:528: DyaK28XltFSqsLk%3D (Pubitemid 26264869)
13. Teramukai S, Kitano T, Kishida Y et al (2009) Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 45: 1950-1958
14. M Paesmans JP Sculier P Libert, et al. 1995 Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1, 052 patients. The European Lung Cancer Working Party J Clin Oncol 13 1221 1230 7738625 1:STN:280:DyaK2M3ls12ntA%3D%3D
15. S Negrier B Escudier F Gomez, et al. 2002 Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie Ann Oncol 13 1460 1468 12196373 10.1093/annonc/mdf257 1:STN:280:DC%2BD38vjvVGitA%3D%3D
16. J Atzpodien P Royston T Wandert, et al. 2003 Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 88 348 353 12569375 10.1038/sj.bjc.6600768 1:STN:280:DC%2BD3s7gtlyntA%3D%3D (Pubitemid 36308143)
17. F Donskov M Hokland N Marcussen, et al. 2006 Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma-results from a randomised phase II trial Br J Cancer 94 218 226 16434984 10.1038/sj.bjc.6602937 1:CAS:528: DC%2BD28XmvVyntw%3D%3D (Pubitemid 43151539)
18. H Schmidt L Bastholt P Geertsen, et al. 2005 Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model Br J Cancer 93 273 278 16052222 10.1038/sj.bjc.6602702 1:CAS:528:DC%2BD2MXmvFensLg%3D (Pubitemid 43080028)
19. H Schmidt S Suciu CJ Punt, et al. 2007 Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial J Clin Oncol 25 1562 1569 17443000 10.1200/JCO.2006.09.0274 1:CAS:528:DC%2BD2sXlsVynur0%3D (Pubitemid 46733083)
20. SR Walsh EJ Cook F Goulder, et al. 2005 Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer J Surg Oncol 91 181 184 16118772 10.1002/jso.20329 1:STN:280:DC%2BD2MvlvFCjtA%3D%3D (Pubitemid 41254421)
21. T Yamanaka S Matsumoto S Teramukai, et al. 2007 The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer Oncology 73 215 220 18424885 10.1159/000127412 (Pubitemid 351630053)
22. Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M (eds) (2006) The Merck manual of diagnosis and therapy, 18th edn. Wiley